Novoheart

Novoheart debuted a new commercial platform to measure true contractility of 3-D engineered cardiac tissue at #SPSVirtual2020 last week. With hardware and software developed by our in-house engineers, the CTScreen is a turnkey yet sophisticated platform that offers precision, reliability, and versatility for drug discovery and cardiac research applications. Click here to read the product brochure: https://bit.ly/362dsgv #Safety Pharmacology Society

Novoheart has participated in the Safety Pharmacology Society Annual Meeting which was held Sept 14-17, 2020. At this year’s virtual meeting, we have launched our new product, the CT Screen, an instrument that offers drug developers an automated screening tool, using the company’s human ventricular Cardiac Tissue Strip (hvCTS).

Novoheart’s approach to the discovery and development of new therapeutics marks an important step away from using mice in traditional testing models, which have limited predictive ability for drug discovery due to key differences in genetic makeup and physiology. Read more here:

‘We foresee within the next decade a shift away from the animal testing which will substantially enhance the efciency of the drug discovery and development process and help deliver safer and more effective drugs to patients in need, in shorter time and at lower cost. Novoheart’s innovations are cutting across costly and time-consuming barriers in the field of drug research. Read about how Novoheart’s MyHeart platform is set to transform the drug development process:

Novoheart has received an exclusive license to combine its MyHeart platform with Harvard’s pioneering tissue-engineered scale model of the heart ventricle and bioreactor technology. The combination will advance the platform’s disease modelling capabilities to an unprecedented level of biofidelity for in vitro human cardiac assays. Read more here:

A look back at a great, in-depth interview with Novoheart’s Dr. Bernard Fermini in European Pharmaceutical Manufacturer. What do you love about your job? Pretty much everything. The challenges of making sure the science is top-notch, working with some of the best minds in the industry, learning something new every day, having the opportunity to shape the career of younger colleagues, contributing to the growth of a new company, making a difference. What else can you ask for! Read more:

Novoheart’s proprietary technologies featured in a recent Friedrich’s Ataxia News feature - 3D Heart Models Suggest Restoring Frataxin Could Treat Cardiac Dysfunction in Friedreich’s Ataxia Read more here:

Novoheart’s new and proprietary microplates, developed with a global pharma, ecompass 96 individual wells, each able to cultivate a single human ventricular Cardiac Tissue Strip (hvCTS) Read more:

Novoheart was recognized among a number of great innovators as part of the 2020 TSX Venture 50. Some inspiring companies to watch in the coming months and years. See the full list of winners here. https://buff.ly/2TsDIZG

Introducing ... Novoheart VP of Scientific Development, Gabriel Wong is an expert in the field of cardiac tissue engineering. He joined Novoheart in 2015 and manages the research team in the application of the MyHeart platform of cardiac tissue constructs in drug screening projects. Read more about the Novoheart leadership team:

By combining Novoheart’s proprietary hvCOC model with our expertise in heart failure, we aim to create the first in vitro model reproducing phenotypic characteristics of heart failure with preserved ejection fraction. This could bridge the gap between in vivo animal models and clinical trials to help accelerate the drug discovery process by providing human-specific preclinical data. - Regina Fritsche Danielson, Senior Vice President, Head of Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca. Read more:

Take a minute to hear Prof. Ron Li discuss with the TSX Venture team the maturing of the 'Human Heart-in-a-jar' technology and its expanding presence in the field of drug discovery and development. #TSXVenture50 #TSX

Introducing ... Novoheart CSO & co-founder Prof. Kevin Costa. Kevin is an inventor of several cardiac tissue engineering technologies and since 2009, has been working with Novoheart co-founder & CEO Prof. Ronald Li to translate such systems into human cells. He is also Director of Cardiovascular Cell and Tissue Engineering at the Icahn School of Medicine at Mount Sinai in New York City. Read more about the Novoheart leadership team: